Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
1 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
0.5 mL (Note: This volume does not allow for repeat testing.)
Gel-barrier tube or red-top tube
Microbially-contaminated or heat-treated specimen; specimen containing particulate matter; grossly hemolyzed, lipemic, or icteric samples
This assay uses indirect immunofluorescence to determine IgG and IgM titers to Coxsackie A serotypes A7, A9, A16, and A24. Recent infections of Coxsackie viruses are characterized by elevated titers of IgG and IgM.
A positive test result does not necessarily indicate current or recent infection as antibodies to Coxsackie species can be detected in uninfected individuals due to moderate passive exposure to infected hosts. It is, therefore, crucial that results from all Coxsackie A serologies correlate with the clinical history of the patient and all other data available to the physician. Samples collected at the early stage of infection (primarily in children) may not yield detectable antibodies. If a recent infection is suspected, a second specimen should be collected 10 to 20 days following the initial collection and tested.
Indirect fluorescent antibody (IFA)
Coxsackie viruses are enteroviruses belonging to the Picornavirus family, which is comprised of strains A and B as well as various serotypes A1-22, 24, and B1-6. Following incubation, a variety of well known diseases can manifest themselves within the host. Coxsackie A is commonly associated with hand, foot, and mouth disease, which primarily affects children younger than 10 years of age. In rare cases, Coxsackie infections may produce mild or subclinical symptoms, yet most infections trigger the onset of flu-like ailments but may include symptoms of other diseases along the lines of pneumonia, hepatitis, and meningitis.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|163295||Coxsackie A IgG/IgM Antibody||163276||Coxsackie A7 IgG||titer||59584-3|
|163295||Coxsackie A IgG/IgM Antibody||163277||Coxsackie A9 IgG||titer||58792-3|
|163295||Coxsackie A IgG/IgM Antibody||163278||Coxsackie A16 IgG||titer||59583-5|
|163295||Coxsackie A IgG/IgM Antibody||163279||Coxsackie A24 IgG||titer||59582-7|
|163295||Coxsackie A IgG/IgM Antibody||163291||Coxsackie A7 IgM||titer||59581-9|
|163295||Coxsackie A IgG/IgM Antibody||163292||Coxsackie A9 IgM||titer||58791-5|
|163295||Coxsackie A IgG/IgM Antibody||163293||Coxsackie A16 IgM||titer||59580-1|
|163295||Coxsackie A IgG/IgM Antibody||163294||Coxsackie A24 IgM||titer||59579-3|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf